Compare Charles River Laboratories Intl. Inc (CRL) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs NEOS S&P 500 High Income ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $298.8 (market cap $14.23B), while NEOS S&P 500 High Income ETF trades at $54 (market cap $12.50B). The key difference: Charles River Laboratories Intl. Inc and NEOS S&P 500 High Income ETF are close in size by market cap, and NEOS S&P 500 High Income ETF is more actively traded (3,058,962 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| CRL | SPYI | |
|---|---|---|
Market Cap | $14.23B | $12.50B |
Volume | 1,176,885 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $310.77 | $54.42 |
52-Week Low | $149.93 | $47.98 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
SPYI trades at $53.995, showing minimal daily movement with a slight 0.03% decline. The technical outlook is bullish based on moving averages, though oscillators remain neutral. Recent news highlights SPYI's role in income-focused portfolios, with coverage discussing both its high distribution yields and potential risks to principal value from covered call strategies.
The outlook for SPYI centers on its income generation appeal amid market volatility, but investors should weigh the trade-off between high yields and potential capital erosion. Key risks include sequence risk in retirement portfolios and the cap on upside during strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
